Coronavirus 2019-2020 thread (no unsubstantiated rumours!)


Hendrik_2000

Brigadier
Now this is a good explanation why Sinovac low effective rate. They include people with mild symptom patient after inoculation that is not included in most other trial. But the vaccine has shown to be effective with people of moderate to high symptom patient. so gadget tool are you listening ?

What happened if there is no Chinese vaccine as the world's rich hoarding and hogging their vaccine
Plus the high tech distribution of western vaccine will preclude poorer nation with no sophisticated cool storage
 
Last edited:

supercat

Junior Member
Now this is a good explanation why Sinovac low effective rate. They include people with mild symptom patient after inoculation that is not included in most other trial. But the vaccine has shown to be effective with people of moderate to high symptom patient. so gadget tool are you listening ?

What happened if there is no Chinese vaccine as the world's rich hoarding and hogging their vaccine
Plus the high tech distribution of western vaccine will preclude poorer nation with no sophisticated cool storage
Let's wait and see if CoronaVac will be approved by Brazilian regulators and included in the WHO COVAX program in the future.

According to Peter Doshi, the associate editor of the BMJ, Pfizer's data need more scrutiny:
“Suspected covid-19”
All attention has focused on the dramatic efficacy results: Pfizer reported 170 PCR confirmed covid-19 cases, split 8 to 162 between vaccine and placebo groups. But these numbers were dwarfed by a category of disease called “suspected covid-19”—those with symptomatic covid-19 that were not PCR confirmed. According to FDA’s report on Pfizer’s vaccine, there were “3410 total cases of suspected, but unconfirmed covid-19 in the overall study population, 1594 occurred in the vaccine group vs. 1816 in the placebo group.”

With 20 times more suspected than confirmed cases, this category of disease cannot be ignored simply because there was no positive PCR test result. Indeed this makes it all the more urgent to understand. A rough estimate of vaccine efficacy against developing covid-19 symptoms, with or without a positive PCR test result, would be a relative risk reduction of 19% (see footnote)—far below the 50% effectiveness threshold for authorization set by regulators. Even after removing cases occurring within 7 days of vaccination (409 on Pfizer’s vaccine vs. 287 on placebo), which should include the majority of symptoms due to short-term vaccine reactogenicity, vaccine efficacy remains low: 29% (see footnote).
Please, Log in or Register to view URLs content!

Russia may be the first country to register the third COVID-19 vaccine from China:

Russia May Be First to Register CanSino Vaccine Outside of China​

CanSino Biologics Inc.’s Russian partner expects local authorities to register the Chinese company’s Covid-19 vaccine soon, potentially marking the first approval for use of the inoculation outside of China.

“All registration procedures have been completed, we expect to get the registration certificate in days,” Nikolay Dodonov, head of Petrovax Pharm’s medical department, said in a phone interview.

The CanSino vaccine is currently undergoing Phase 3 trials and was granted emergency approval in China, where it has only been used to inoculate members of the military to date.
...

Petrovax, owned by the country’s richest man, Vladimir Potanin, got permission for a local Phase 3 trial of the CanSino vaccine in August and applied to register it in November, according to Dodonov.

Petrovax completed injections of 500 volunteers in its local trial in November and has analyzed the results of 200 so far, Dodonov said. Of those assessed, 149 received the inoculation and had antibody levels four times higher than the minimum threshold for immunity, he said.

Petrovax, which is also helping conduct CanSino’s international trial in Russia, plans to complete its study by May.
Please, Log in or Register to view URLs content!
 

taxiya

Colonel
Registered Member
Please, Log in or Register to view URLs content!

View attachment 67483


To summarize the Brazil trials:
Efficacy report in the Brazilian trials was tiered: 50% full efficacy, 78% in stopping mild symptoms, 100% efficiency against medium to high severity and death.
I wonder how the mRNA data would look like if test conducted in the same manner. Or they never did their trail in such manner. It looks more and more to me that the US was really rushing their vaccine and deliberately choose a testing regime that would produce a better result.
 

emblem21

Junior Member
Registered Member
Talk about slow... They couldn't release data for 9 months! And they want China to know there is a new virus on day 1.
Sadly enough, it does serve these people right and if they keep up with the double standard, may they continue to suffer since really, the fact they expect the world of China and yet they cannot even try to do anything to suggest they are any where near China’s level just shows how undeserving of all the good fortune they have had after all this time. If a virus mutates enough to target the Anglo’s instead because they let the virus mutate to that extent, well they will have no one else to blame although by that point. It will do no good
 

Top